SCHEDULE: Vanguard Group Reports Zero Stake in Madrigal Pharma

The Vanguard Group has reported a 0% beneficial ownership in Madrigal Pharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 5 to Schedule 13G for Madrigal Pharmaceuticals Inc.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of Madrigal Pharmaceuticals Inc.'s Common Stock.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Madrigal Pharmaceuticals Inc. as it primarily reflects an internal reporting change by The Vanguard Group rather than a direct investment decision or performance update for Madrigal.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Madrigal Pharmaceuticals Inc.'s future performance or The Vanguard Group's investment strategy beyond the reporting change.

Industry Context

StockSavvy.ai notes that changes in beneficial ownership reported by large institutional investors like The Vanguard Group are common, especially when they involve internal reorganizations or shifts in reporting methodologies. This particular filing reflects a structural change in how Vanguard's various entities report their holdings, rather than a direct investment or divestment decision regarding Madrigal Pharmaceuticals Inc. by the broader Vanguard ecosystem.

Stakeholder Impact

• Shareholders of Madrigal Pharmaceuticals Inc. may observe a change in the reported institutional ownership structure, with The Vanguard Group, Inc. no longer appearing as a beneficial owner in aggregate filings, though underlying holdings by Vanguard subsidiaries may persist and be reported separately.

Key Dates

Keywords

Madrigal Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Internal Realignment